
|Videos|June 10, 2019
Dr. Gadgeel on Docetaxel Plus Trametinib in KRAS-Mutated Recurrent NSCLC
Author(s)Shirish M. Gadgeel, MD
In this video, Shirish M. Gadgeel, MD, of Rogel Cancer Center, University of Michigan, discusses combo docetaxel/trametinib in G12C or non-G12C KRAS mutation-positive, recurrent NSCLC.
Advertisement
In this video, Shirish M. Gadgeel, MD, of Rogel Cancer Center, University of Michigan, spoke with Cancer Network about the results of a phase II study (
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
Exploring The Impact of ADTs on Cardiac Risk in Prostate Cancer Treatment
3
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC
4
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
5




































